Objective: To identify the frequency of insurance related issues with intravenous immunoglobulin (IVIg) therapy approval for patients with autoimmune gastrointestinal dysmotility (AGID) and the outcomes of missed IVIg treatments.
Due to the profound effect of novel coronavirus disease 2019 (COVID-19) on healthcare systems, surgical programs across the country have paused surgical operations and have been utilizing virtual visits to help maintain public safety. For those…